Bayer bets on ophthalmology with Perfuse buy: full analysis
Bayer is moving deeper into ophthalmology with a planned acquisition of Perfuse Therapeutics valued at up to $2.45 billion, a deal centered on PER-001, a Phase II intravitreal implant for glaucoma and diabetic retinopathy. Announced on May 6, 2026, the transaction includes $300 million upfront and up to $2.15 billion in milestone payments, and would give Bayer full rights to Perfuse’s lead program once antitrust and shareholder approvals are complete. Bayer framed the buy as a strategic fit with its ophthalmology footprint and a way to complement its pipeline in diseases with significant unmet need. (bayer.com)
The backdrop is important. Bayer already has a major presence in eye care through Eylea in Europe, but industry coverage has pointed to pressure on that franchise as the product matures and faces lifecycle challenges. Against that backdrop, Perfuse offers Bayer a mid-stage asset with a different scientific angle: instead of focusing on intraocular pressure reduction in glaucoma or VEGF suppression in retinal disease, PER-001 targets the endothelin pathway, which Perfuse says is implicated in reduced blood flow, inflammation, and cell death across multiple ischemia-driven ocular diseases. (fiercebiotech.com)
Perfuse’s own materials describe PER-001 as a bio-erodible intravitreal implant delivered with a 25-gauge applicator and designed for sustained release over roughly six months. In a June 24, 2025 announcement, the company said two randomized, controlled Phase II studies suggested functional and structural improvements in both glaucoma and diabetic retinopathy, with a favorable safety and tolerability profile across 60 treated patients. In glaucoma, Perfuse highlighted visual field improvement and optic nerve blood flow findings. In diabetic retinopathy, it reported gains in contrast sensitivity, peripheral vision, and imaging-based measures of ischemia and leakage. (perfusetherapeutics.com)
That early dataset appears to be the core value driver behind the acquisition. Bayer’s release says PER-001 could become one of the first disease-modifying treatments for both glaucoma and diabetic retinopathy, and specifically notes its potential to improve visual field in glaucoma and contrast sensitivity while reducing ischemia in diabetic retinopathy. Fierce Biotech similarly characterized the deal as a bet on a midphase eye-disease prospect with early signs of visual benefit. (bayer.com)
Expert reaction, at least from prior Perfuse communications, has been notably enthusiastic. In Perfuse’s 2025 release, Joel Schuman, MD, of Wills Eye Hospital called non-IOP-based optic nerve protection a “holy grail” in glaucoma care, while Arshad Khanani, MD, said the diabetic retinopathy findings suggested a new way to improve visual function by addressing underlying neurovascular disease. Those comments came through company-issued materials, so they should be read as supportive expert perspective rather than independent post-deal analysis. Still, they help explain why Bayer was willing to pay a potentially multibillion-dollar price for a Phase II asset. (perfusetherapeutics.com)
Why it matters: For veterinary professionals, this is less about a direct companion-animal application today and more about where ophthalmology innovation is heading. The deal underscores how much value biopharma is placing on therapies that aim to preserve or restore visual function through neurovascular mechanisms, especially in chronic diseases where current standards of care are often incomplete. That has relevance for veterinarians following retinal degeneration, glaucoma management, sustained-release ocular drug delivery, and the broader possibility that human ophthalmic innovation could eventually inform animal health R&D or specialty referral care. It also signals that ophthalmology remains an active dealmaking category, even when programs are still short of pivotal-stage evidence. (bayer.com)
What to watch: The biggest near-term issue is development timing. Perfuse said in 2025 that pivotal trials were planned for the second half of 2025, but industry reporting noted that no Phase III PER-001 study was visible in the federal trial database as of the acquisition announcement, and Bayer’s release kept the asset in Phase II without giving a new timeline. That suggests Bayer may need to revisit trial design, endpoints, or sequencing before the program advances. Veterinary professionals tracking translational eye care should watch for regulatory updates, pivotal-trial registration, and whether Bayer expands the platform into other ischemia-driven ocular diseases such as age-related macular degeneration or retinal vein occlusion. (perfusetherapeutics.com)